Hologic, Inc. (NASDAQ:HOLX) Position Increased by NEOS Investment Management LLC

NEOS Investment Management LLC raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 28.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,183 shares of the medical equipment provider’s stock after buying an additional 2,483 shares during the period. NEOS Investment Management LLC’s holdings in Hologic were worth $806,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brooklyn Investment Group grew its holdings in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 145 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its holdings in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 169 shares during the period. UMB Bank n.a. lifted its stake in Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after buying an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc boosted its holdings in shares of Hologic by 3.6% in the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $61.32 on Monday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67. The company has a 50 day moving average price of $65.24 and a two-hundred day moving average price of $73.24.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. BNP Paribas upgraded Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Raymond James reissued an “outperform” rating and set a $90.00 price target (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.